CABOMETYX (Ipsen Pty Ltd)
Product name
CABOMETYX
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
163 (255 working days)
Active ingredients
cabozantinib (S)-malate
Registration type
EOI
Indication
CABOMETYX (film-coated tablet) in combination with nivolumab is now also indicated for the first-line treatment of advanced renal cell carcinoma.